Atox Bio, a Ness Ziona, Israel-based developer of therapeutics for diseases mediated by an excessive inflammatory response, has raised $3.25m in funding.
The investment was co-led by Esperante and a private US-based investor.
The company intends to use the funding to advance AB103, currently in phase 2 clinical studies (at 7 leading surgical trauma centers in the US) for the treatment of Necrotizing Soft Tissue Infections (NSTI). AB103 is a rationally designed short peptide acting as a CD28 modulator regulating the host’s inflammatory response. In October 2011, the FDA has granted AB103 an orphan drug designation.
NSTI includes several distinctive clinical diagnoses that share clinical features representing the most severe types of infections involving the skin, skin structures and soft tissue and having a high mortality rate. To date, there are no approved treatments for NSTI.
Led by CEO Dan Teleman, Atox Bio will be included as one of the portfolio companies of Integra Holdings, a holding company currently formed by Yissum, the technology transfer company of the Hebrew University of Jerusalem.
FinSMEs
19/12/2011